Interv Akut Kardiol. 2010;9(6):316-318

Is there any link between myocardial reinfarction after a major orthopedic surgery

Tomáš Roubíček, Vladimír Hraboš
Kardiocentrum Krajské nemocnice Liberec a. s.

and a lack of effectiveness of antiplatelet therapy ?

Extensive orthopedic procedures, such as total hip replacement, represent an important thrombotic state of the organism as a response

to tissue injury. We present a 63 years old patient who suffered an acute myocardial infarction as a first symptom of coronary heart

disease early after orthopedic surgery. Myocardial infarction was treated by urgent percutaneous coronary intervention of the right

coronary artery. The patient was taking dual antiplatelet therapy (aspirin and clopidogrel). The patient suffered myocardial re-infarction

due to stent thrombosis on day 9. Optical aggregometry using inducers arachidonic acid and ADP confirmed the lack of effectiveness

of antiplatelet therapy. For this reason, prasugrel therapy was initiated with good effect on platelet aggregation. Follow-up tests of

platelet aggregation after 3 months demonstrated normal sensitivity to aspirin with the lasting good effect of prasugrel. This case study

shows that platelet aggregation is a dynamic process which is influenced by many factors. Different mechanisms leading to thrombotic

state, including a major orthopedic surgery, may temporarily reduce the effect of antiplatelet drugs.

Keywords: thrombotic state, in-stent thrombosis, prasugrel

Published: December 10, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roubíček T, Hraboš V. Is there any link between myocardial reinfarction after a major orthopedic surgery. Interv Akut Kardiol. 2010;9(6):316-318.
Download citation

References

  1. Vila PM, Zafar MU, Badimon JJ. Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. Platelets 2009; 20: 531-538. Go to original source... Go to PubMed...
  2. Hoshino K, Horiuchi H, Tada T, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009; 73: 336-342. Go to original source... Go to PubMed...
  3. Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009; 5: 965-972. Go to original source... Go to PubMed...
  4. Azam S M, Jozic J. Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. Transl Res 2009; 154: 309-313. Go to original source... Go to PubMed...
  5. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009; 29: 332-336. Go to original source... Go to PubMed...
  6. Cola C, Brugaletta S, Martin Yuste V, et al. Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag 2009; 5: 101-119. Go to original source... Go to PubMed...
  7. Szucs G, Ajzner E, Muszbek L, et al. Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic orthopedic surgery. J Orthop Sci 2009; 14: 484-490. Go to original source... Go to PubMed...
  8. Peled E, Keren Y, Halachmi S, et al. Patients aged 80 and older undergoing orthopedic or urologic surgery: a prospective study focusing on perioperative morbidity and mortality. Gerontology 2009; 55: 517-522. Go to original source... Go to PubMed...
  9. Pampuch A, Cerletti C, De Gaetano G. Comparison of VASPphosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773. Go to original source... Go to PubMed...
  10. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15: 295-301. Go to original source... Go to PubMed...
  11. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251. Go to original source... Go to PubMed...
  12. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363: 930-942.
  13. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015. Go to original source... Go to PubMed...
  14. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.